0001183740-22-000011.txt : 20220113 0001183740-22-000011.hdr.sgml : 20220113 20220113144603 ACCESSION NUMBER: 0001183740-22-000011 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20220113 DATE AS OF CHANGE: 20220113 EFFECTIVENESS DATE: 20220113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Valeo Pharma Inc. CENTRAL INDEX KEY: 0001904395 IRS NUMBER: 000000000 STATE OF INCORPORATION: Z4 FISCAL YEAR END: 1031 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-429329 FILM NUMBER: 22528801 BUSINESS ADDRESS: STREET 1: 16667, HYMUS BLVD. CITY: KIRKLAND STATE: A8 ZIP: H9H 4R9 BUSINESS PHONE: 514-693-8832 MAIL ADDRESS: STREET 1: 16667, HYMUS BLVD. CITY: KIRKLAND STATE: A8 ZIP: H9H 4R9 D 1 primary_doc.xml X0708 D LIVE 0001904395 Valeo Pharma Inc. 16667, HYMUS BLVD. KIRKLAND A8 QUEBEC, CANADA H9H 4R9 514-693-8832 CANADA (FEDERAL LEVEL) None None Corporation true Guy-Paul Allard 16667, HYMUS BLVD. KIRKLAND A8 QUEBEC, CANADA H9H 4R9 Executive Officer Richard J. Mackay 16667, HYMUS BLVD. KIRKLAND A8 QUEBEC, CANADA H9H 4R9 Executive Officer Director Steve Saviuk 16667, HYMUS BLVD. KIRKLAND A8 QUEBEC, CANADA H9H 4R9 Executive Officer Director Frederic Fasano 16667, HYMUS BLVD. KIRKLAND A8 QUEBEC, CANADA H9H 4R9 Executive Officer Director Michael G. Wells 16667, HYMUS BLVD. KIRKLAND A8 QUEBEC, CANADA H9H 4R9 Director Maureen C. Breenan 16667, HYMUS BLVD. KIRKLAND A8 QUEBEC, CANADA H9H 4R9 Director Vincent P. Hogue 16667, HYMUS BLVD. KIRKLAND A8 QUEBEC, CANADA H9H 4R9 Director Michel Trudeau 16667, HYMUS BLVD. KIRKLAND A8 QUEBEC, CANADA H9H 4R9 Director Luc Mainville 16667, HYMUS BLVD. KIRKLAND A8 QUEBEC, CANADA H9H 4R9 Executive Officer Nelly Komari 16667, HYMUS BLVD. KIRKLAND A8 QUEBEC, CANADA H9H 4R9 Executive Officer Helen Saviuk 16667, HYMUS BLVD. KIRKLAND A8 QUEBEC, CANADA H9H 4R9 Executive Officer Jeff Skinner 16667, HYMUS BLVD. KIRKLAND A8 QUEBEC, CANADA H9H 4R9 Executive Officer Nathalie Therrien 16667, HYMUS BLVD. KIRKLAND A8 QUEBEC, CANADA H9H 4R9 Executive Officer Michelle Brien 16667, HYMUS BLVD. KIRKLAND A8 QUEBEC, CANADA H9H 4R9 Executive Officer Pharmaceuticals Decline to Disclose 06b false 2021-12-09 true true true true true true 12% convertible unsecured subordinated debenture, maturing on December 31, 2024, convertible into common shares. false 0 Desjardins Securities International Inc. 112417 None None 1170 Peel Street, Suite 300 Montreal A8 QUEBEC, CANADA H3B 0A9 WI WISCONSIN false 787400 787400 0 Total Offering Amount represents aggregate principal amount of C$1,000,000 convertible debenture. There is no guarantee that the convertible debenture will be converted into common shares of the Issuer. Exchange rate C$1: US$0.7874. false 1 0 55118 true Finder's Fees represents cash fee of C$70,000, converted to US$, were paid to Desjardins Securities International Inc. 0 false Valeo Pharma Inc. /s/ Guy Paul Allard Guy Paul Allard VP Legal Affairs and Corporate Secretary 2021-12-23